S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

Baxter International - BAX Price Target & Analyst Ratings

$40.07
+0.84 (+2.14%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$39.52
$40.41
50-Day Range
$37.58
$47.01
52-Week Range
$37.35
$80.72
Volume
5.64 million shs
Average Volume
6.67 million shs
Market Capitalization
$20.22 billion
P/E Ratio
N/A
Dividend Yield
2.89%
Price Target
$55.14

Baxter International Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$55.14
37.62% Upside
High Prediction$75.00
Average Prediction$55.14
Low Prediction$43.00
TypeCurrent
3/28/22 to 3/28/23
1 Month Ago
2/26/22 to 2/26/23
3 Months Ago
12/28/21 to 12/28/22
1 Year Ago
3/28/21 to 3/28/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
11 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$55.14$55.14$67.33$95.25
Predicted Upside37.62% Upside15.19% Upside13.33% Upside15.09% Upside
Get Baxter International Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.

BAX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BAX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Baxter International Stock vs. The Competition

TypeBaxter InternationalMedical CompaniesS&P 500
Consensus Rating Score
2.17
2.64
2.47
Consensus RatingHoldBuyHold
Predicted Upside37.62% Upside1,993.26% Upside22.47% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/13/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$58.00 ➝ $44.00+8.64%
2/13/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$63.00 ➝ $54.00+31.87%
2/10/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$52.00 ➝ $43.00+4.50%
2/10/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$55.00 ➝ $44.00+9.62%
2/10/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$70.00 ➝ $45.00+12.11%
2/6/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$73.00 ➝ $60.00+28.53%
1/5/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/3/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$66.00 ➝ $55.00+7.91%
12/19/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$68.00 ➝ $55.00+10.64%
12/15/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$69.00 ➝ $51.00-2.49%
11/3/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Amit Hazan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetSell$60.00 ➝ $53.00+4.47%
10/12/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$62.00+11.09%
7/29/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$95.00 ➝ $70.00+19.25%
7/18/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$85.00 ➝ $75.00+15.54%
2/18/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$88.00 ➝ $91.00+10.79%
9/5/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
7/29/2021Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$85.00 ➝ $82.00+5.29%
3/18/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
2/5/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$99.00 ➝ $95.00+21.83%
9/4/2020Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
(Data available from 3/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BAX Price Target - Frequently Asked Questions

What is Baxter International's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Baxter International stock is Hold based on the current 1 sell rating, 8 hold ratings and 3 buy ratings for BAX. The average twelve-month price prediction for Baxter International is $55.14 with a high price target of $75.00 and a low price target of $43.00. Learn more on BAX's analyst rating history.

Do Wall Street analysts like Baxter International more than its competitors?

Analysts like Baxter International less than other Medical companies. The consensus rating for Baxter International is Hold while the average consensus rating for medical companies is Buy. Learn more on how BAX compares to other companies.

Is Baxter International being downgraded by Wall Street analysts?

Over the previous 90 days, Baxter International's stock had 3 downgrades by analysts.

Does Baxter International's stock price have much upside?

According to analysts, Baxter International's stock has a predicted upside of 15.19% based on their 12-month price targets.

What analysts cover Baxter International?

Baxter International has been rated by Bank of America, Barclays, Citigroup, Cowen, KeyCorp, Morgan Stanley, Raymond James, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:BAX) was last updated on 3/28/2023 by MarketBeat.com Staff